Review Article

Bisphosphonate Associated Osteonecrosis of the Jaw: An Update on Pathophysiology, Risk Factors, and Treatment

Lars Rasmusson1 and Jahan Abtahi2

1 Department Oral and Maxillofacial Surgery, The Sahlgrenska Academy, University of Gothenburg, P.O. Box 450, 405 30 Gothenburg, Sweden
2 Maxillofacial Unit, Linköping University Hospital, 581 85 Linköping, Sweden

Correspondence should be addressed to Lars Rasmusson; lars.rasmusson@gu.se

Received 6 May 2014; Accepted 18 July 2014; Published 1 September 2014

Academic Editor: Giuliano Ascani

Copyright © 2014 L. Rasmusson and J. Abtahi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Osteonecrosis of the jaw in patients treated with bisphosphonates is a relatively rare but well known complication at maxillofacial units around the world. It has been speculated that the medication, especially long-term i.v. bisphosphonate treatment, could cause sterile necrosis of the jaws. The aim of this narrative review of the literature was to elaborate on the pathological mechanisms behind the condition and also to gather an update on incidence, risk factors, and treatment of bisphosphonate associated osteonecrosis of the jaw. In total, ninety-one articles were reviewed. All were published in internationally recognized journals with referee systems. We can conclude that necrotic lesions in the jaw seem to be following upon exposure of bone, for example, after tooth extractions, while other interventions like implant placement do not increase the risk of osteonecrosis. Since exposure to the bacterial environment in the oral cavity seems essential for the development of necrotic lesions, we believe that the condition is in fact chronic osteomyelitis and should be treated accordingly.

1. Introduction

The first report describing osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates came 2003 [1]. Since then this condition, sometimes called BRONJ (bisphosphonate-related osteonecrosis of the jaw), has shown increasing interest by dentists and oral-maxillofacial surgeons. It is defined as an area of exposed bone in the maxillofacial region that does not heal within 8 weeks in a patient who is currently receiving bisphosphonate medication and has not had radiation to the head-neck region. The diagnosis is usually made clinically. It is believed mainly to be associated with high dose intravenous bisphosphonate therapy, but sometimes the condition occurs also in patients with low-dose osteoporotic treatment. The current perception among dentists and oral-maxillofacial surgeons seems to be that low-dose bisphosphonate treatment for osteoporosis is linked to an increased incidence of ONJ, while on the other hand endocrinologists may suggest increased prescribing to decrease the incidence of osteoporotic fractures. This review aims to elaborate on the pathogenic mechanisms behind bisphosphate associated necrosis of the jaw and incidence, prevention, and treatment of the condition.

2. Methods

The present paper is authored as a narrative review contribution. Data synthesis and analysis: the articles were picked and sorted according to their corresponding key area of focus.

3. Results

Ninety-one studies were included, consisting of 9 reviews, 79 original papers, 2 letters and 1 thesis.

4. Discussion

4.1. Structure and Bioactivity of Bisphosphonates. Bisphosphonates (BPs) are antiresorptive drugs that act specifically on osteoclasts, thereby maintaining bone density and
is high, expectedly as ion binding. Lin and coworkers \[13\] observed in physiological pH (7.4). Therefore, plasma protein binding to the pores of tight junctions between the epithelial cells. Sorbed by the paracellular route, which means passage through across epithelial barriers. Consequently, BPs must be absorbed by the paracellular route, which means passage through the pores of tight junctions between the epithelial cells.

The gastrointestinal uptake of orally administrated BPs is low with a bioavailability of 0.3–0.7\% \[11, 12\]. The poor lipophilicity which prevents transcellular transport absorption of BPs can probably be attributed to their very poor lipophilicity, which prevents transcellular transport across epithelial barriers. Consequently, BPs must be absorbed by the paracellular route, which means passage through the pores of tight junctions between the epithelial cells.

Bisphosphonates are completely ionized in blood at physiological pH (7.4). Therefore, plasma protein binding is high, expectedly as ion binding. Lin and coworkers \[13\] demonstrated that, in rats, alendronate binds to serum albumin and this binding seems to be dependent on serum calcium levels and pH. Plasma protein binding in human has been found to be less with alendronate showing an unbound fraction 22\% compared to 4\% in rats \[13\].

Intravenous administration of a single dose of alendronate leads on the other hand to rapid accumulation of this drug in bone tissue, approximately 30\% in 5 min and 60\% in 1 hour \[14\]. The half-life in plasma is 1-2 hour and this rapid elimination is due to bone uptake and renal clearance. Once incorporated into the bone, bisphosphonates are liberated again only when the bone in which it was deposited is resorbed. Therefore, the rate of the bone turnover influences the half-life of this drug \[15\].

The distribution of BPs in bone is determined by blood flow and favours deposition at sites of the skeleton undergoing active resorption \[14\]. Neither orally nor intravenously administrated BPs are metabolized in humans \[16\].

### 4.2. Mechanism of Action

During bone resorption, bisphosphonates impair the ability of the osteoclasts to form the ruffled border, to adhere to the bony surface and to produce the protons necessary for continued bone resorption \[17–19\].

Following cellular uptake, a characteristic morphological feature of bisphosphate-treated osteoclasts is the lack of a ruffled border, leading to reduced adhesion to the bony surface. Bisphosphonates also promote osteoclast apoptosis by decreasing osteoclast progenitor development and recruitment \[20\]. Nevertheless, following exposure to certain bisphosphonates, inhibition of the osteoclast proton pumping H-ATPase phosphatases and lysosomal enzymes could also contribute to the loss of resorptive capacity of osteoclasts \[21, 22\].

Clodronate are the first generation, nonnitrogen-containing bisphosphonates which entered osteoclasts, incorporated into nonhydrolyzable analogues of adenosine triphosphate (ATP) and converted into methylene-containing (AppCp type) analogues of ATP. Accumulation of these toxic by-products interferes with mitochondrial function and ultimately leads to apoptosis of osteoclasts \[23, 24\].

In contrast, nitrogen-containing bisphosphonates (such as zoledronate and pamidronate) act by inhibiting farnesyl pyrophosphate (FPP) synthase and geranylgeranyl pyrophosphate (GGPP) synthase, two key enzymes in the mevalonate pathway. As a consequence, the disruption of the mevalonate pathway by nitrogen-containing bisphosphonates results in impaired protein prenylation and activation of small GTPases such as Ras, Rho, Rac and Cdc42. The small GTPases are important signalling proteins regulating osteoclast morphology, cytoskeleton arrangement, membrane ruffling, and trafficking and cell survival \[10, 25\].

It has been suggested that another target of BPs could be the osteoblast, which in turn influence the osteoclasts. It has been shown experimentally that BPs inhibit the expression of receptor activator of NF-kappa B ligand (RANK-L) in rat osteoblast cells and increase the expression of osteoprotegerin.

---

**Figure 1:** Chemical structure of pyrophosphate and bisphosphate. R1 and R2 signify the side chains of bisphosphonate.
More recently, ONJ is defined as a complication of disease with impairment of bone resorption and remodeling [44, 45]. ONJ has also been seen in osteopetrosis, a rare inherited disorder.

A therapy has been investigated by Zuffetti et al. [43]. By the 5-year follow-up, no implant failure had been recorded in test group.

In a recent series of randomized controlled trials, local application of BPs during total joint surgery has been shown to reduce migration of metal prostheses as measured by radiostereometry [38].

In a recent series of randomized controlled trials, local application of BPs during total joint surgery has been shown to reduce migration of metal prostheses as measured by radiostereometry [38].

In the randomized study of 16 patients, a thin bisphosphonate-eluting fibrinogen coating improved the fixation of dental implants in human bone Abtahi et al. [42]. The efficacy of the topical administration of bisphosphonates in implant therapy has been investigated by Zuffetti et al. [43]. By the 5-year follow-up, no implant failure had been recorded in test group.

4.4. Osteonecrosis of the Jaw (ONJ). Historically, osteonecrosis of the jaw (ONJ) was first reported by occupational exposure to white phosphorus which was called “phossy jaw” [44, 45]. ONJ has also been seen in osteopetrosis, a rare inherited disease with impairment of bone resorption and remodeling [46]. More recently, ONJ is defined as a complication of head and neck radiotherapy [47]. The definition of ONJ is nonhealing exposed jawbone for more than 8 weeks in patients receiving BPs and without any local radiation therapy. Clinically, the disease presents as exposed alveolar bone that becomes evident following a surgical procedure such as tooth removal or periodontal therapy [48, 49] Figure 2.

Signs and symptoms that may occur before the development of clinically detectable osteonecrosis include pain, tooth mobility, mucosal swelling, erythema, and ulceration. The incidence of ONJ in bone malignancy cases, mainly treated with high dose intravenous bisphosphonates, is about 1–12% [48, 49].

Wang and coworkers [50] found that the incidence of ONJ was at least 3.8% in patients with multiple myeloma, 2.5% in breast cancer patients, and 2.9% in prostate cancer patients. In osteoporosis, bisphosphonate associated osteonecrosis of the jaw is rare and the incidence may not be greater than the natural background incidence. Epidemiological studies have indicated an estimated incidence of less than 1 cases per 100 000 person-years of exposure to oral bisphosphonates.

4.5. Pathogenesis. The etiology of ONJ remains uncertain. Initially, when the condition was called bisphosphonate-related osteonecrosis of the jaw (BRONJ) [48] its similarities with radiation-induced osteonecrosis led to the assumption that the condition started with sterile necrosis of the jaw bone. Therefore, the term osteonecrosis was used otherwise reserved for sterile bone death usually because of impaired blood supply. At that time, it was speculated that BPs could cause osteonecrosis through effects on blood vessels in bone, possibly by inhibition of vascular endothelial growth [51].

Later, it has been suggested that the condition does not begin as a form of classical osteonecrosis but in fact osteomyelitis from the start [52, 53].

Bacterial contamination with Actinomyces and Staphylococcus may play a role in maintaining osteomyelitic wounds and because maxillofacial bone tissue containing BPs will resorb slowly, it is conceivable that contaminated bone cannot be removed fast enough to prevent the development of chronic osteomyelitis. This view is supported by the fact that similar lesions appear after treatment with anti-RANK-L antibodies that reduces osteoclast recruitment [54]. Thus, it appears that reduced resorptive activity is a key factor behind the impaired healing capacity of these lesions [55].

We suggest that the term BRONJ should be avoided and replaced by the term bisphosphonate associated osteomyelitis of the jaw, BAOJ, which better reflects the conditions aetiology.

Antibiotics can prevent the development of ONJ-like lesions in a rat model [56]. One hundred twenty animals underwent tooth extraction and received combination of dexamethasone and pamidronate during different time periods. Animals which received the same treatment except for the addition of penicillin showed four times less ONJ-like lesions than the other group. There is no clinical study on the use of antibiotics associated with ONJ. However, in the clinical situation antibiotics has its use since the condition is considered osteomyelitis of the jaw.

The antiangiogenic role of bisphosphonate is still unclear and ONJ proceeds despite the use of antibiotics in some cases. One explanation could be the fact that bacterial contamination maintains chronic osteomyelitis of the jaws. Another explanation is perhaps the reduced microcirculation of the gingiva causing the soft tissue unable to heal.
Corticosteroids and chemotherapeutics have been suggested as factors that can predispose to ONJ or increase the risk of developing ONJ; the duration of BP therapy also appears to be related to the likelihood of developing necrosis with longer treatment regimens associated with a greater risk [55]. The time to develop osteonecrosis after i.v. zoledronate treatment was in mean 1.8 years, after i.v pamidronate 2.8 years and after oral BP therapy, like alendronate, the mean time was 4.6 years [57].

Numerous studies have explored the toxic effect of BPs on a variety of epithelial cells [58–62]. There is clear documentation of bisphosphonate toxicity to gastrointestinal epithelia [63]. It has been suggested that high concentrations of bisphosphonate in the oral cavity (bone tissue) disrupt the oral mucosa [64]. Failure of healing of the soft tissue may cause secondary infection of the underlying bone. However, this theory has not yet been accepted by investigators. Recently, in a rat model of ONJ, following tooth extraction a high dose of alendronate (200 μg/kg) did not cause ONJ-like lesions [65]. When calculated as dose per body weight per day, the rat dose was 100 times higher than the human dose.

4.6. Clinical Characteristics. Blood supply to the cortical bone is derived from the periosteum and exposed bone surface is indicating necrosis in the underlying bone layers. The condition can then progress into a more severe bony lesion with nerve disturbances, mobile teeth, fistulas, and in the end fracture [66]. Pain is common and these signs and symptoms are often evident in patients with jaw bone osteomyelitis that are not on BP treatment. Radiographs may show sclerotic bone, sclerotic lamina dura around individual teeth, and widened periodontal ligaments but there are no report published indicating specific features for BP associated osteomyelitis [67].

4.7. Incidence. The incidence of BP associated osteomyelitis can be divided into 2 groups: the high dose i.v treated cancer patients and osteoporotic patients. In a systematic review, Kahn et al. found that, for the first group, the cumulative incidence varied from 1% to 12% after 36 months of treatment [66]. However, most of the reported cases have been related to intravenous use of bisphosphonates (zoledronic and pamidronic acid) to control metastatic bone disease or multiple myeloma. The incidence of ONJ in these studies ranges from 4 to 10% [1, 68, 69] and the mean time of onset varies from 1 to 3 years [55, 70, 71].

Osteoporosis is a common and costly condition that impaired quality of life [71]. It is estimated that 10 million individuals (aged >50 years) in the United States have osteoporosis, by 2010 [72]. Few studies have reported the prevalence of ONJ in persons receiving exclusive oral bisphosphonate therapy. No cases of ONJ were reported by Felsenberg et al. among clinical trials involving almost 17000 patients [73]. The authors estimated the worldwide reporting rate of ONJ to be <3/100,000 years of exposure [72]. In osteoporosis patients, by systemic review Kahn et al. estimated incidence of ONJ to be <1 case per 100,000 person-years of exposure [66]. Similar findings have been reported by German investigators, as determined by cases captured by a German Central Registry [73, 74]. By using postmarketing surveillance method Abtahi et al. identified one case of ONJ among 952 patients, who had received chronic oral bisphosphonate therapy [75]. Moreover, these findings contrast to those from an Australian study, which identified ONJ cases by nationwide maxillofacial surgeon survey [70].

The trigger for developing necrotic bone in BP treated patients seems to be dental extractions. A review of 114 cases of BP associated ONJ in Australia showed that 73% of the cases occurred after dental extractions. The frequency of ONJ in BP treated osteoporotic patients was 0.01%–0.04% and if dental extraction occurred 0.09%–0.34%. In patients on BPs for bone malignancies, the incidence was 0.33%–1.15% and after dental extractions 6.7%–9.1% [70].

4.8. Risk Factors. There are general and local risk factors for development of ONJ.

**General risk factors** include malignancies, chemotherapy, glucocorticoid treatment, and high dose or long-term bisphosphonate treatment [48, 66].

**Local risk factors** include anatomical features where protruding cortical bone with thin mucosal coverage like tori and exostoses implies greater risk for necrosis as well as periodontal disease, any surgical intervention which breaks the mucosal lining, especially tooth extractions [48, 67]. In an experimental study by Abtahi and coworkers [75], it was shown that immediate soft tissue coverage after tooth extraction prevented ONJ completely whilst all noncovered sites developed ONJ in osteoporotic rats treated with alendronate, Figure 3.

The use of bisphosphonates is associated with the development of ONJ in some patients. Length of exposure seems to be the most important risk factor for this complication with an estimated range from 1.6 to 4.7 years, depending on BPs type [55]. Subsequent to ONJ development the minimum duration of use was reported to be 6 months [76, 77]. Barash and coworkers showed that the risk for development of ONJ begins within 2 years of treatment, for both cancer and noncancer patients, showing that even the less potent bisphosphonates are linked to ONJ after a relatively brief treatment period [76]. Furthermore, for noncancer patients this risk seems to increase substantially after 5 years. This highlights the importance of drug holiday after 5 years of treatment. In a prospective study by Bamias et al. the incidence of ONJ was studied among patients treated with bisphosphonates for bone metastases. The incidence of ONJ increased with time to exposure from 1.5% among patients treated for 4 to 12 months to 7.7% for treatment for 37 to 48 months [77].

4.9. Bisphosphonates and Oral Implant Therapy. In a systematic review from 2009, Madrid and Sanz [78] included studies where patients had been on BP treatment for 1–4 years before implant placement. None of the patients developed osteonecrosis up to 36 months postoperatively
Figure 3: Histological sections showing the region of the second molar 14 days after extraction in male Sprague-Dawley rat. (a) Control rat with no treatment, (b) BP treated with coverage, and (c) BP treated without coverage. Note necrotic tissue.

and the implant survival rate ranged from 95 to 100%. This may indicate that exposed/noncovered bone is necessary for bacterial invasion and an osteomyelitic process.

Furthermore, in a study from 2010, Koka and coworkers found high implant survival rates for both bisphosphonate users and nonusers in postmenopausal women [79].

4.10. Treatment. The optimal treatment strategy for ONJ is still to be established. Cessation of BP treatment will not be sufficient. A multidisciplinary team approach for evaluation and management of the conditions is recommended including a dentist, an oral-maxillofacial surgeon, and an oncologist. In early stages, surgical debridement and coverage has been successful [80]. Hyperbaric oxygen (HBO) is an effective adjunctive therapy in situations in which normal wound healing is impaired and the effects of HBO therapy have been discussed by several investigators [81, 82]. The authors showed that patients with ONJ, adjunctive HBO therapy had remission or improvement in over 62.5% of patients. Laser therapy at low intensity has been reported for treatment of ONJ by improving reparative process, increasing osteoblastic index, and stimulating lymphatic and blood capillaries growth [83–85].

Segmental osteotomies are recommended only for severe cases [86–89], due to relatively high levels of morbidity and impaired quality of life for the patients [90].

In a study by Holzinger et al. [91], 108 patients with bisphosphonate therapy underwent surgery and 88 patients were followed for a mean period of 337 days. Surgical treatment improved the stage distribution from 19% stage I, 56% stage II, and 25% stage III to 59% intact mucosa, 19% stage I and 13% stage II and 8% stage III. The improvement in the stage of disease achieved by surgery was statistically significant. However, the choice between surgery and conservative therapy is a difficult issue and must be made on an individual basis.

Recently there have been discussions regarding the applicability of “drug holidays” to minimize long-term bisphosphonate exposure and avoid potential adverse events such as ONJ. However, given the long half-life of bisphosphonates in bone (measured in years) whether or not temporary cessation of treatment with these agents would reduce associated risks is not known. These questions require further study.

Antibiotics: Samples should be taken for culture and sensitivity testing before starting ab treatment. Traditionally, the antibiotics of choice to treat osteomyelitis will include Flucloxacillin or Clindamycin.

Prevention is a cornerstone to reduce the incidence of ONJ and before starting BP therapy, the patient should be referred for thorough dental evaluation to identify and treat any potential source of infection. Start of BP therapy should be delayed by 4–6 weeks to allow appropriate bone healing [90].

The treatment of bisphosphonate-related osteonecrosis of the jaw is generally difficult. For this reason, prevention plays a predominant role in the management of this condition.
5. Conclusion

The present narrative review, based on experimental and clinical original papers as well as previous reviews, indicates that osteonecrosis of the jaw in BP treated patients seems to be triggered by exposed bone and subsequent bacterial contamination, typically after dental extraction, and that sterile necrosis of the jaw is unlikely. We therefore suggest that the condition could be coined “Bisphosphonate associated osteomyelitis of the jaw.”

Conflict of Interests

Both authors declared that they have no conflict of interests.

References

[1] R. E. Marx, “Pamidronate Aredia and zoledronate induced avascular necrosis of the jaws: a growing epidemic,” Journal of Oral and Maxillofacial Surgery, vol. 61, no. 9, pp. 1115–1117, 2003.
[2] S.-J. Qui, G. Gibson, K. Lundin-Cannon, and M. Schaffler, Osteocyte Apoptosis after Acute Matrix Injury in Compact Bone, The Orthopaedic Research Society, San Francisco, Calif, USA, 1997.
[3] R. E. Coleman, “Future direction in the treatment and prevention of bone metastases,” American Journal of Clinical Oncology, vol. 25, pp. 2–8, 2002.
[4] I. Holen and R. E. Coleman, “Bisphosphonates as treatment of bone metastases,” Current Pharmaceutical Design, vol. 16, no. 11, pp. 1262–1271, 2010.
[5] G. I. Im, S. A. Qureshi, J. Kenney, H. E. Rubash, and A. S. Shanbhag, “Osteoblast proliferation and maturation by bisphosphonates,” Biomaterials, vol. 25, no. 18, pp. 4105–4115, 2004.
[6] S. C. Cremer, G. Pillai, and S. E. Papapoulos, “Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis,” Clinical Pharmacokinetics, vol. 44, no. 6, pp. 551–570, 2005.
[7] E. van Beek, C. W. G. M. Löwik, F. H. Ebetino, and S. E. Papapoulos, “Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure–activity relationships,” Bone, vol. 23, no. 5, pp. 437–442, 1998.
[8] R. G. Russell, Z. Xia, J. E. Dunford et al., “Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy,” Annals of the New York Academy of Sciences, vol. 1117, pp. 209–257, 2007.
[9] G. H. Nancollas, R. Tang, R. J. Phipps et al., “Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite,” Bone, vol. 38, no. 5, pp. 617–627, 2006.
[10] R. G. G. Russell and M. J. Rogers, “Bisphosphonates: from the laboratory to the clinic and back again,” Bone, vol. 25, no. 1, pp. 97–106, 1999.
[11] B. J. Gertz, S. D. Holland, W. F. Kline, B. K. Matuszewski, and A. G. Porras, “Clinical pharmacology of alendronate sodium,” Osteoporosis International, vol. 3, no. 3, pp. 13–16, 1993.
[12] P. T. Daley-Yates, D. J. Dodwell, M. Pongchaidecha, R. E. Coleman, and A. Howell, “The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases,” Calcified Tissue International, vol. 49, no. 6, pp. 433–435, 1991.
[13] J. H. Lin, I. Chen, F. A. Deluna, and M. Hichens, “Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 267, no. 2, pp. 670–675, 1993.
[14] J. H. Lin, I. W. Chen, and F. A. deLuna, “On the absorption of alendronate in rats,” Journal of Pharmaceutical Sciences, vol. 83, no. 12, pp. 1741–1746, 1994.
[15] J. H. Lin, “Bisphosphonates: a review of their pharmacokinetic properties,” Bone, vol. 18, no. 2, pp. 75–85, 1996.
[16] W. R. Michael, W. R. King, and J. M. Wakim, “Metabolism of disodium etidronate in the rat, rabbit, dog and monkey,” Toxicology and Applied Pharmacology, vol. 21, no. 4, pp. 503–515, 1972.
[17] G. A. Rodan and H. A. Fleisch, “Bisphosphonates: mechanisms of action,” Journal of Clinical Investigation, vol. 97, no. 12, pp. 2692–2696, 1996.
[18] M. Sato, W. Grasser, N. Endo et al., “Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure,” The Journal of Clinical Investigation, vol. 88, no. 6, pp. 2095–2105, 1991.
[19] S. Colucci, V. Minielli, G. Zambonin et al., “Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces,” Calcified Tissue International, vol. 63, no. 3, pp. 230–235, 1998.
[20] D. E. Hughes, K. R. Wright, H. L. Uy et al., “Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo,” Journal of Bone and Mineral Research, vol. 10, no. 10, pp. 1478–1487, 1995.
[21] P. David, H. Nguyen, A. Barbier, and R. Baron, “The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+-ATPase,” Journal of Bone and Mineral Research, vol. 11, no. 10, pp. 1498–1507, 1996.
[22] R. Felix, R. G. Russell, and H. Fleisch, “The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes,” Biochimica et Biophysica Acta, vol. 429, no. 2, pp. 429–438, 1976.
[23] J. C. Frith, J. Mönkkönen, G. M. Blackburn, R. G. G. Russell, and M. J. Rogers, “Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5’-(β,γ-dichloromethylene) triphosphate, by mammalian cells in vitro,” Journal of Bone and Mineral Research, vol. 12, no. 9, pp. 1358–1367, 1997.
[24] A. J. Roelofs, K. Thompson, S. Gordon, and M. J. Rogers, “Molecular mechanisms of action of bisphosphonates: current status,” Clinical Cancer Research, vol. 15, pp. 6222–6230, 2006.
[25] S. P. Luckman, D. E. Hughes, F. Coxon, R. G. G. Russell, and M. J. Rogers, “Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras,” Journal of Bone and Mineral Research, vol. 13, no. 4, pp. 581–589, 1998.
[26] P. S. Mackie, J. L. Fisher, H. Zhou, and P. F. M. Choong, “Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line,” British Journal of Cancer, vol. 84, no. 7, pp. 951–958, 2001.
[27] V. Viercke, G. Emons, V. Lauck et al., “Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts,” Biochemical and Biophysical Research Communications, vol. 291, no. 3, pp. 680–686, 2002.
[28] S.-J. Qui, G. Gibson, K. Lundin-Cannon, and M. Schaffler, “Calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 267, no. 2, pp. 670–675, 1993.
M. Weinreb, H. Quartuccio, J. G. Seedor et al., “Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys,” *Journal of Periodontal Research*, vol. 29, no. 1, pp. 35–40, 1994.

A. Yaffe, M. Iztkovich, Y. Earon, I. Alt, R. Lilov, and I. Binderman, “Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats,” *Journal of Periodontology*, vol. 68, no. 9, pp. 884–889, 1997.

K. Wermelin, P. Aspenberg, P. Linderbäck, and P. Tengvall, “Bisphosphonate coating on titanium screws increases mechanical fixation in rat tibia after two weeks,” *Journal of Biomedical Materials Research A*, vol. 86, no. 1, pp. 220–227, 2008.

M. Yoshinari, Y. Oda, T. Inoue, K. Matsuzaka, and M. Shimono, “Bone response to calcium phosphate-coated and bisphosphonate-immobilized titanium implants,” *Biomaterials*, vol. 23, no. 14, pp. 2879–2885, 2002.

B. Peter, O. Gauthier, S. Laib et al., “Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats,” *Journal of Biomedical Materials Research,* vol. 76, no. 1, pp. 133–143, 2006.

A. Roshan-Ghias, J. Arnoldi, P. Procter, and D. P. Pioletti, “In vivo assessment of local effects after application of bone screws delivering bisphosphonates into a compromised cancellous bone site,” *Clinical Biomechanics*, vol. 26, no. 10, pp. 1039–1043, 2011.

V. A. Stadelmann, O. Gauthier, A. Terrier, J.-M. Bouler, and D. P. Pioletti, “Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study,” *European Cells and Materials*, vol. 16, pp. 10–16, 2008.

G. Friedl, R. Radl, C. Stihsen, P. Rehak, R. Aigner, and R. Windhager, “The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty: a randomized, double-blind, controlled trial,” *Journal of Bone and Joint Surgery*, vol. 91, no. 2, pp. 274–281, 2009.

J. M. Wilkinson, A. C. Eagleton, I. Stockley, N. F. A. Peel, A. J. Hamer, and R. Eastell, “Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial,” *Journal of Orthopaedic Research*, vol. 23, no. 1, pp. 1–8, 2005.

M. Hilding, L. Ryd, S. Toksvig-Larsen, and P. Aspenberg, “Clodronate prevents prosthetic migration: a randomized radiostereometric study of 50 total knee patients,” *Acta Orthopaedica Scandinavica*, vol. 71, no. 6, pp. 553–557, 2000.

A. R. Pradeep, M. Kumari, N. S. Rao, and S. B. Naik, “1% alendronate gel as local drug delivery in the treatment of class II furcation defects: a randomized controlled clinical trial,” *Journal of Periodontology*, vol. 84, no. 3, pp. 307–315, 2013.

A. Sharma and A. R. Pradeep, “Clinical efficacy of 1% Alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: a randomized, controlled clinical trial,” *Journal of Periodontology*, vol. 83, no. 1, pp. 11–18, 2012.

A. Shar and A. R. Pradeep, “Clinical efficacy of 1% alendronate gel in adjunct to mechanotherapy in the treatment of aggressive periodontitis: a randomized controlled clinical trial,” *Journal of Periodontology*, vol. 83, no. 1, pp. 19–26, 2012.

J. Abtahi, P. Tengvall, and P. Aspenberg, “A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants,” *Bone*, vol. 50, no. 5, pp. 1148–1151, 2012.

F. Zuffetti, T. Testori, M. Capelli, M. C. Rossi, and M. del Fabbro, “The topical administration of bisphosphonates in implant surgery: a randomized split-mouth prospective study with a follow-up up to 5 years,” *Clinical Implant Dentistry and Related Research*, 2013.

A. E. Miles, “Phosphorus necrosis of the jaw: “phossy jaw”,” *British Dental Journal*, vol. 133, no. 5, pp. 203–206, 1972.

M. L. Myers and J. D. McGlothlin, “Matchmakers’ “phossy jaw” eradicated,” *The American Industrial Hygiene Association Journal*, vol. 57, no. 4, pp. 330–332, 1996.

M. A. Vance, “Osteonecrosis of the jaw and bisphosphonates: a comparison with white phosphorus, radium, and osteopetrosis,” *Clinical Toxicology*, vol. 45, no. 7, pp. 753–762, 2007.

T. Reuthner, T. Schuster, U. Mende, and A. C. Kübler, “Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients: a report of a thirty year retrospective review,” *International Journal of Oral and Maxillofacial Surgery*, vol. 32, no. 3, pp. 289–295, 2003.

R. E. Marx, Y. Sawatari, M. Fortin, and V. Broumand, “Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment,” *Journal of Oral and Maxillofacial Surgery*, vol. 63, no. 11, pp. 1567–1575, 2005.

S. L. Ruggiero, B. Mehrotra, T. J. Rosenberg, and S. L. Engroff, “Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases,” *Journal of Oral and Maxillofacial Surgery*, vol. 62, no. 5, pp. 527–534, 2004.

E. P. Wang, L. B. Kaban, G. J. Strewler, N. Raje, and M. J. Troulis, “Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy,” *Journal of Oral and Maxillofacial Surgery*, vol. 65, no. 7, pp. 1328–1331, 2007.

D. Santini, B. Vincenzi, G. Avvisati et al., “Pamidronate induces modifications of circulating angiogenic factors in cancer patients,” *Clinical Cancer Research*, vol. 8, no. 5, pp. 1080–1084, 2002.

P. Aspenberg, “Osteonecrosis of the jaw: what do bisphosphonates do?” *Expert Opinion on Drug Safety*, vol. 5, no. 6, pp. 743–745, 2006.

T. B. Dodson, N. S. Raje, P. A. Caruso, and A. E. Rosenberg, “Case 9–2008—a 65-year-old woman with a nonhealing ulcer of the jaw,” *The New England Journal of Medicine*, vol. 358, no. 12, pp. 1214–1219, 2008.

K. H. Taylor, L. S. Middlefell, and K. D. Mizen, “Osteonecrosis of the jaws induced by anti-RANK ligand therapy,” *British Journal of Oral and Maxillofacial Surgery*, vol. 48, no. 3, pp. 221–223, 2010.

S. B. Woo, J. W. Hellstein, and J. R. Kalmar, “Systematic review: bisphosphonates and osteonecrosis of the jaws,” *Annals of Internal Medicine*, vol. 144, no. 10, pp. 753–756, 2006.

P. López-Jornet, F. Camacho-Alonso, A. Martínez-Canovas, F. Molina-Miano, F. Gómez-García, and V. Vicente-Ortega, “Peri-operative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws,” *Journal of Oral and Maxillofacial Surgery*, vol. 69, no. 10, pp. 2488–2493, 2011.

P. K. Palaska, V. Cartos, and A. I. Zavras, “Bisphosphonates and time to osteonecrosis development,” *Oncologist*, vol. 14, no. 11, pp. 1154–1166, 2009.

I. M. Twiss, R. de Water, J. Den Hartigh et al., “Cytotoxic effects of pamidronate on monolayers of human intestinal
epithelial (Caco-2) cells and its epithelial transport,” *Journal of Pharmaceutical Sciences*, vol. 83, no. 5, pp. 699–703, 1994.

[59] I. M. Twiss, O. Pas, W. Ramp-Koempansch, J. Den Hartigh, and P. Vermeij, “The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium,” *Journal of Bone and Mineral Research*, vol. 14, no. 5, pp. 784–791, 1999.

[60] A. Blank, “N-bisphosphonates cause gastric epithelial injury independent of effect on the microcirculation,” *Alimentary Pharmacology and Therapeutics*, vol. 13, no. 12, pp. 1675–1682, 1999.

[61] A. A. Reszka, J. Halasy-Nagy, and G. A. Rodan, “Nitrogen-containing bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation,” *Molecular Pharmacology*, vol. 59, no. 2, pp. 193–202, 2001.

[62] E. Giraudo, M. Inoue, and D. Hanahan, “An amino-bisphosphonate targets MMP-9—expressing macrophages and angiogenesis to impair cervical carcinogenesis,” *The Journal of Clinical Investigation*, vol. 114, no. 5, pp. 623–633, 2004.

[63] A. R. Reid, M. J. Bolland, and A. B. Grey, “Is bisphosphate-associated osteonecrosis of the jaw caused by soft tissue toxicity?” *Bone*, vol. 41, no. 3, pp. 318–320, 2007.

[64] J. Abtahi, F. Agholme, O. Sandberg, and P. Aspenberg, “Bisphosphate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone,” *Journal of Oral Pathology & Medicine*, vol. 41, no. 6, pp. 494–499, 2012.

[65] A. Kahn, G. Sandor, E. Dore et al., “Bisphosphonate associated osteonecrosis of the jaw,” *The Journal of Rheumatology*, vol. 36, pp. 478–490, 2009.

[66] J. Abtahi, *Bisphosphonates and implants in the jaw bone [M.S. thesis]*, University of Linkoping, Linkoping, Sweden, 2013.

[67] V. Fusco, A. Loidoris, G. Colella, P. Vescovi, and G. Campisi, “Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment,” *Breast*, vol. 19, no. 5, pp. 432–433, 2010.

[68] P. Vescovi, G. Campisi, V. Fusco et al., “Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRON): a retrospective analysis of 567 cases in an Italian multicenter study,” *Oral Oncology*, vol. 47, no. 3, pp. 191–194, 2011.

[69] T. Mavrokokki, A. Cheng, B. Stein, and A. Goss, “Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia,” *Journal of Oral and Maxillofacial Surgery*, vol. 65, no. 3, pp. 415–423, 2007.

[70] J. B. Bilizkian, “Osteonecrosis of the jaw—do bisphosphonates pose a risk?” *The New England Journal of Medicine*, vol. 355, no. 22, pp. 2278–2281, 2006.

[71] “Statement by Merck & Company: Incorporated: Regarding Fosamax (alendronate sodium) and rare cases of osteonecrosis of the jaw,” *Product News*, 2008, http://www.mercknewsroom.com.

[72] D. Felsenberg, B. Hoffmeister, and M. Amling, “Kiefernekrosen nach hoch dosierter bisphosphonattherapie,” *Deutsches Ärzteblatt*, vol. 103, article 3078, 2006.

[73] P. Sambrook, I. Olver, and A. Goss, “Bisphosphonates and osteonecrosis of the jaw,” *Australian Family Physician*, vol. 35, no. 10, pp. 801–803, 2006.

[74] J. Abtahi, F. Agholme, and P. Aspenberg, “Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model,” *International Journal of Oral and Maxillofacial Surgery*, vol. 42, no. 5, pp. 632–636, 2013.

[75] A. Barasch, J. Cunha-Cruz, F. A. Curro et al., “Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN,” *Journal of Dental Research*, vol. 90, no. 4, pp. 439–444, 2011.

[76] A. Bamias, E. Kastritis, C. Bamia et al., “Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors,” *Journal of Clinical Oncology*, vol. 23, no. 34, pp. 8580–8587, 2005.

[77] C. Madrid and M. Sanz, “What impact do systemically administered bisphosphonates have on oral implant therapy? A systematic review,” *Clinical Oral Implants Research*, vol. 20, no. 4, pp. 87–95, 2009.

[78] S. Koka, N. M. S. Babu, and A. Norell, “Survival of dental implants in post-menopausal bisphosphonate users,” *Journal of Prosthodontic Research*, vol. 54, no. 3, pp. 108–111, 2010.

[79] J. Lemound, A. Eckardt, H. Kokenmüller et al., “Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap,” *Clinical Oral Investigations*, vol. 16, no. 4, pp. 1143–1152, 2012.

[80] P. Vescovi, E. Merigo, M. Meleti et al., “Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw,” *International Journal of Dentistry*, vol. 2014, Article ID 107690, 8 pages, 2014.

[81] J. J. Freiberger, “Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws,” *Journal of Oral and Maxillofacial Surgery*, vol. 67, no. 5, supplement, pp. 96–106, 2009.

[82] P. Vescovi, E. Merigo, M. Manfredi et al., “Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases,” *Photomedicine and Laser Surgery*, vol. 26, no. 1, pp. 37–46, 2008.

[83] M. Scoletta, P. G. Arduino, L. Reggio, P. Dalmasso, and M. Mozzati, “Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study,” *Photomedicine and Laser Surgery*, vol. 28, no. 2, pp. 179–184, 2010.

[84] U. Romeo, A. Galanakis, C. Marias et al., “Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: preliminary results,” *Photomedicine and Laser Surgery*, vol. 29, no. 7, pp. 447–452, 2011.

[85] E. R. Carlson and J. D. Basile, “The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws,” *Journal of Oral and Maxillofacial Surgery*, vol. 67, no. 5, pp. 85–95, 2009.

[86] T. Mücke, J. Koschinski, H. Deppe et al., “Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws,” *Journal of Cancer Research and Clinical Oncology*, vol. 137, no. 5, pp. 907–913, 2011.

[87] R. Seth, N. D. Futran, D. S. Alam, and P. D. Knott, “Outcomes of vascularized bone graft reconstruction of the mandible in
bisphosphonate-related osteonecrosis of the jaws,” *Laryngoscope*, vol. 120, no. 11, pp. 2165–2171, 2010.

[89] O. Filleul, E. Crompot, and S. Saussez, “Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases,” *Journal of Cancer Research and Clinical Oncology*, vol. 136, no. 8, pp. 1117–1124, 2010.

[90] S. L. Ruggiero, J. Fantasia, and E. Carlson, “Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management,” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology*, vol. 102, no. 4, pp. 433–441, 2006.

[91] D. Holzinger, R. Seemann, C. Klug et al., “Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs),” *Oral Oncology*, vol. 49, no. 1, pp. 66–70, 2013.